Back HCV Treatment

HCV Treatment

EASL 2014: Sofosbuvir + Simeprevir Shows High Cure Rates for Hep C Patients with or without Cirrhosis

A 12-week oral regimen of sofosbuvir (Sovaldi) plus simeprevir (Olysio) without pegylated interferon or ribavirin led to sustained virological response in 93% of genotype 1 hepatitis C patients with either absent to moderate liver fibrosis or with advanced fibrosis or cirrhosis, according to data from the COSMOS trial presented last week at the 49th EASL International Liver Congress in London.

alt

Read more:

Coverage of the 2014 EASL International Liver Congress

HIVandHepatitis.com coverage of the 49th European Association for the Study of the Liver's International Liver Congress (EASL 2014) in London, April 9-13, 2014.

Conference highlights include new interferon-free treatments for hepatitis C, hepatitis B and delta, and management of liver disease complications such as cirrhosis and hepatocellular carcioma.

Full listing by topic

Conference web site

4/13/14

alt

EASL 2014: European Liver Specialists Recommend Use of Newest Hepatitis C Drugs

The European Association for the Study of the Liver (EASL) has issued new guidelines for the treatment of hepatitis C, which recommend that wherever possible, patients should be treated with the newest direct-acting antivirals. The guidelines also recommend physicians should "mix and match" antivirals from different companies to get the most potent regimens.

alt

Read more:

Coverage of the 2014 EASL International Liver Congress

HIVandHepatitis.com coverage of the 49th European Association for the Study of the Liver's International Liver Congress (EASL 2014) in London, April 9-13, 2014.

Conference highlights include new interferon-free treatments for hepatitis C, hepatitis B and delta, and management of liver disease complications such as cirrhosis and hepatocellular carcioma.

Full listing by topic

Conference web site

4/13/14

alt

EASL 2014: Sofosbuvir + Ledipasvir Cures More than 90% of First-time and Retreated Genotype 1 Patients

A coformulation of sofosbuvir and ledipasvir taken for as little as 8 weeks produced high sustained response rates across the board for participants in the Phase 3 ION trials, including people with HCV genotype 1 starting treatment for the first time, prior non-responders, and people with liver cirrhosis, according to findings presented this week at the 49thEASL International Liver Congress in London. Results were also published online in the New England Journal of Medicine.

alt

Read more: